Biodexa Pharmaceuticals-ADRBDRX
13F holders, Q2 2026 (June 30)7holders +6
0new positions
0sold out
$2.90avg. 13F price*
At the end of Q2 2026, 7 institutions reported holding Biodexa Pharmaceuticals-ADR (BDRX) in their 13F filings, up 6 from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($43K), GAMMA Investing LLC ($4K) and Allied Private Wealth LLC ($1K).
- Company
- Biodexa Pharmaceuticals-ADR
- CUSIP
- 59564R872
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 5 shares bought and 6,371 shares sold, net −6,366 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Armistice Capital, LLC | 0.00% | Reduce -24.1% | 14,809 | $43K |
| GAMMA Investing LLC | 0.00% | Reduce -56.4% | 1,203 | $4K |
| Allied Private Wealth LLC | 0.00% | — | 489 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -80.8% | 29 | $84 |
| UBS Group AG | 0.00% | Reduce -1.6% | 25 | $73 |
| Hilton Head Capital Partners, LLC | 0.00% | No change | 6 | $17 |
| Caitong International Asset Management Co., Ltd | 0.00% | Add +2400.0% | 5 | $15 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals-ADR the manager owns.